BioInvestor

Icahn Boosts Stake in Amylin to 6.5%, Seeks Additional Talks

Icahn could well be on to something. My guess is that he'll probably copy--or at least do something similar--to the group that muscled in on Ligand Pharmaceuticals (NASDAQ: LGND) two years ago. The situations aren't similar, but the outcome could be the same.

He'll likely push to transform AMLN into an R&D play by demanding that products be sold to a major pharma or biotech company. The company might even offload some of the cash generated in the sale in the form of an extraordinary dividend. I'll dig into AMLN's financials a little more.

The weight loss numbers sound good--better than those reported by Arena Pharmaceuticals (NASDAQ:ARNA), which is set to file for marketing approval next year.

Pfizer Fizzles, Fast Money Recap (4/18/08)

I'd suggest no only hold PFE, but buy more. In fact, why not have one share transferred into your name, that way you can participate in the purchase plan, paying no commissions!